Image by Mathew Schwartz from Unsplash
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Psilocybin, the commonly-known primary compound in magic mushrooms, is widely believed to be a leading candidate in a revolution in mental healthcare.
Psilocybin owes its popularity to a less-known but arguably more important compound called psilocin.
Exclusively-natural psychedelic drug development company Filament Health Corp. (NEO: FH, OTC: FLHLF, FSE: 7QS) recently announced Food and Drug Administration (FDA) approval to start a clinical trial using both psilocybin and psilocin.
Psilocin Versus Psilocybin: How They Differ and How They Relate
Psilocin and psilocybin are closely related — with one key difference. They are both found in magic mushrooms, but psilocybin is not bioactive in humans, meaning that on its own it has no hallucinogenic effect. In the human body, psilocybin converts into psilocin, which causes the hallucinogenic effects associated with magic mushrooms.
Despite the potential benefits of directly administering psilocin, it has been little researched because it is very challenging to make stable synthetic psilocin, and naturally extracting it was deemed impossible. Filament Health states that it has for the first time developed proprietary technology to produce formulations of stable natural psilocin and psilocybin from magic mushrooms.
Trial Details and Importance
The phase 1 clinical trial will include 20 …